Broad Coverage or Concentrated Bets? Analyzing the Differences Between Healthcare Funds VHT and XPH Sep 11, 2026 Life Science
From $275 to $461, UnitedHealth Regains Confidence Through a Turnaround Script Sep 9, 2026 Life Science
AbbVie’s Diversification Bet Gradually Shows Results, While Pfizer Seeks a Second Takeoff Through Its GLP-1 and Oncology Pipelines Sep 5, 2026 Life Science
Pfizer Trades Below 10x P/E, But Does That Signal a Value Trap or a Long-Term Opportunity? Sep 4, 2026 Life Science
Eli Lilly Swallows Merida, Expanding Pipeline with Another Strategic Acquisition Sep 3, 2026 Life Science
Gene-Editing Pioneer CRISPR Therapeutics Worth a Bet Before Year-End? Two Catalysts Await Release Sep 3, 2026 Life Science
GLP-1 Concept Stock Amylyx Soars 247% Year-to-Date: How Much Room Remains for Upside? Sep 2, 2026 Life Science
Kimberly-Clark’s Merger Acquisition Hangs in the Balance? Market Doubts and Potential Opportunities Coexist Sep 1, 2026 Financial Service, Life Science
Ark Invest Goes Against the Grain: Wood Bets on Nvidia and the Gene-Editing Arena Sep 1, 2026 Life Science
Eli Lilly Is on an M&A Spree—Will the $2.88 Billion Merida Deal Be Enough to Diversify? Aug 31, 2026 Life Science
How to Choose Between Two Major Pharmaceutical Themed ETFs? Aug 28, 2026 Financial Service, Life Science
Rasonque’s Lightning Approval Validates Druckenmiller’s Bet on Revolution Medicines Aug 28, 2026 Life Science
Clinical-Stage Biotechnology Company Biohaven Sees Dual Positive Developments During the Week Aug 28, 2026 Life Science
